Skip to main content

Table 2 Subjects' echocardiography data at baseline and after 26 weeks of treatment.

From: Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes

Value

Pioglitazone group

(n = 15)

Insulin glargine group

(n = 15)

P-value

LVDD (mm)

47.6 ± 4.0

48.7 ± 4.5

0.37

IVS (mm)

10.2 ± 0.9

10.4 ± 1.6

0.85

POST (mm)

9.0 ± 1.0

9.1 ± 1.4

0.95

LVM (g)

160 ± 33

173 ± 56

0.55

LVD vol (ml)

104 ± 23

101 ± 21

0.88

LVS vol (ml)

39 ± 11

36 ± 11

0.34

EF (%)

62 ± 5

65 ± 5

0.21

LA vol (ml)

55 ± 14

58 ± 19

0.56

Change LVM (%)

7 ± 14

1 ± 11

0.25

Change LVD vol (%)

11 ± 19

1 ± 5

0.02

Change LVS vol (%)

2 ± 15

2 ± 13

0.74

Change EF (%)

6 ± 10

0 ± 6

0.09

Change LA vol (%)

17 ± 17

2 ± 6

<0.01